The online version of this article (https://doi.org/10.1245/s10434-018-6660-x) contains supplementary material, which is available to authorized users.
Presented at the triennial World Melanoma Congress, Brisbane, Australia, 2017; the Canadian Society of Surgical Oncology Annual Symposium, Vancouver Island, Canada, 2017, winning first-place prize; the British Association of Plastic, Reconstructive and Aesthetic Surgeons Winter Meeting, London, UK, 2017; the International Pigmented Cell International Congress, Denver, CO, USA, 2017; and the European Association of Dermato-Oncology International Congress, Athens, Greece, 2017.
In the peripheral blood, the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) change in response to malignancy. These biomarkers are associated with adverse outcomes in numerous cancers, but the evidence is limited in relation to melanoma. This study sought to investigate the association between these biomarkers and survival in Stages I–III cutaneous melanoma.
This multicenter cohort study investigated a consecutive series of patients who underwent wide excision of biopsy-proven cutaneous melanoma and sentinel lymph node biopsy during a 10-year period. The baseline NLR and PLR were calculated immediately before sentinel lymph node biopsy. Adjusted hazard ratios (HRs) for overall and melanoma-specific survival were generated.
Overall, 1351 patients were included in the study. During surveillance, 184 of these patients died (14%), with 141 of the deaths (77%) attributable to melanoma. Worse overall survival was associated with a baseline NLR lower than 2.5 [HR 2.2; 95% confidence interval (CI) 2.0 to 2.3; p < 0.001] and a baseline PLR lower than 100 (HR 1.8; 95% CI 1.7 to 1.8; p < 0.001). Melanoma-specific survival also was worse, with a baseline NLR lower than 2.5 (HR 1.9; 95% CI 1.6 to 2.2; p < 0.001) and a baseline PLR lower than 100 (HR 1.9; 95% CI 1.7 to 2.2; p < 0.001). The 5-year survival for patients with sentinel lymph node metastases and a low NLR and PLR was approximately 50%.
This study provides important new data on biomarkers in early-stage melanoma, which contrast with biomarker profiles in advanced disease. These biomarkers may represent the host inflammatory response to melanoma and therefore could help select patients for adjuvant therapy and enhanced surveillance.
Supplementary material 1 (DOCX 20 kb)10434_2018_6660_MOESM1_ESM.docx
Cancer Research UK. Skin Cancer Statistics (Internet), 2015. Retrieved at http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/. Accessed October 2017.
Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI J Natl Cancer Inst. 2014;106:124. CrossRef
Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Prev Biomarkers. 2014;23:1204–12. CrossRef
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL TA. AJCC Cancer Staging Manual. 7th ed. Springer New York, LLC, New York, NY, 2010.
Newton Bishop JA. Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma. Retrieved at https://clinicaltrials.gov/ct2/show/N. Accessed October 2017.
- Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
MBBS, DipHR, MClinEd, MRCS, FHEA Ryckie G. Wade
MRes Alyss V. Robinson
BSc(Hons), MBChB, MRCS Michelle C. I. Lo
BSc, MSc, GradStat, PhD Claire Keeble
BM, BCh, MA, FRCP, PhD Maria Marples
BA, MBBS, MRCS(Eng), FRCS(Plast) Donald J. Dewar
MD, FRCS(Plast) Marc D. S. Moncrieff
MBChB, BSc, FRCS(Plast) Howard Peach
- Springer International Publishing
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II